PGP and Parkinson disease: For example, it is hypothesized that reduced P-glycoprotein (P-gp) activity increases the risk of PD through the accumulation of neurotoxic substances, which is supported by the high level of verapamil (a P-gp substrate) observed in the midbrains of patients with PD [21].